The single most common mistake in peptide research protocol design is applying one cycling framework to all compounds. GH secretagogues, tissue repair peptides, and metabolic GLP agonists are mechanistically distinct — and their cycling logic follows directly from their mechanisms. Using a 12-week on/4-week off schedule for BPC-157 makes no more sense than cycling Retatrutide like a GH secretagogue. This guide builds the protocol from the biology up.
All compounds and protocols in this guide are for in vitro and in vivo laboratory research use only. Evo Peptides compounds are not approved for human consumption or therapeutic use. Researchers must comply with applicable institutional and regulatory requirements.
The 3 Cycling Paradigms
Before designing a cycling protocol for any research peptide, the first question is: which paradigm does this compound belong to? The answer determines everything — whether to cycle at all, how long to run, when to stop, and what off-cycle behavior to expect.
Receptor Desensitization: The Science Behind GH Cycling
Understanding why GH secretagogues need cycling requires understanding receptor kinetics. The ghrelin receptor — GHS-R1a — is a G-protein coupled receptor (GPCR). Like all GPCRs, it has a documented pathway for internalization under continuous agonist stimulation.
The 2004 Camina et al. study (Endocrinology) established the mechanistic framework: GHS-R1a desensitization and endocytosis follow standard GPCR internalization kinetics. The receptor is phosphorylated by GRK (GPCR kinase), arrestin-mediated internalization follows, and recycling occurs over hours to days in the absence of continued stimulation. In chronic dosing scenarios over weeks, cumulative internalization outpaces recycling — the effective receptor surface density drops and GH pulse amplitude decreases.
Desensitization vs. Suppression
GH secretagogue cycling addresses receptor desensitization — not GH axis suppression. Unlike exogenous GH (which feeds back to suppress GHRH and GH secretion), peptide secretagogues do not suppress endogenous GH production. The off-cycle is for receptor recycling only, not GH axis recovery. This is why peptide cycling does not require a post-cycle therapy (PCT) protocol analogous to anabolic steroid use.
GH Secretagogue Cycling Protocol
GH secretagogues — compounds that stimulate GH release through ghrelin receptor agonism (GHRPs) or GHRH pathway activation (sermorelin, tesamorelin, CJC-1295) — are the compounds most studied with structured cycling protocols in research literature.
The 8–12/4 Framework
The 8–12 week on / 4 week off protocol is the most documented framework for GH secretagogue research:
- Weeks 1–2 (Loading): Begin at 50–75% of target dose. Allows tolerance assessment and avoids excessive early GH response. GHS-R1a sensitivity is highest in this phase.
- Weeks 3–8 (Active Phase): Full target dose. GH pulse amplitude is optimized. Peak window for data collection on GH-dependent endpoints.
- Weeks 9–12 (Extended/Monitor): Continue only if GH response remains strong. Monitor for diminishing returns — flattening IGF-1 trajectories or reduced endpoint response signal receptor accumulation beginning.
- Weeks 13–16 (Off Phase): Complete cessation for 4 weeks. GHS-R1a recycling occurs over 2–4 weeks. Endogenous GH production continues normally throughout — no suppression concern.
Tesamorelin, which carries FDA approval and has formal pharmacokinetic data, uses continuous daily administration in clinical protocols without explicit cycling — suggesting that at therapeutic doses the receptor dynamics may differ from higher-dose research secretagogue protocols. Researchers should reference the specific compound's pharmacological profile rather than applying the 8–12/4 framework universally to all secretagogues.
Tissue Repair Peptide Protocols
BPC-157, TB-500, and GHK-Cu operate through angiogenesis, cell migration, and gene expression pathways — not through receptor agonism susceptible to the same internalization dynamics as GHS-R1a. The cycling logic for these compounds is therefore fundamentally different.
Goal-Oriented Blocks, Not Calendar Cycles
The key protocol insight: tissue repair peptides are discontinued based on endpoint achievement, not a fixed calendar. A 4-week protocol that achieves its tissue repair endpoint should be stopped at week 4. An 8-week protocol that shows ongoing measurable recovery at week 8 may be extended to week 10. The off-period follows endpoint achievement, not a predetermined schedule.
- Acute phase (Days 1–14): BPC-157 at full dose daily. TB-500 at loading frequency (2–3× weekly). Establish vascular support at injury site.
- Active repair (Weeks 3–6): Both compounds at maintenance frequency. Peak collagen synthesis and cell migration window.
- Endpoint assessment (Week 6–8): Evaluate functional, histological, or biomechanical endpoint. If target achieved, discontinue. If recovery ongoing, extend 2–4 weeks.
- Post-protocol: No mandatory off-cycle length. Allow 2–4 weeks before reassessing whether a second course is warranted.
Metabolic GLP Agonist Protocols
Retatrutide (GLP-3 RT) and Tirzepatide (GLP-2 TRZ) belong to a fundamentally different paradigm. The STEP 1 trial extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism) documented that subjects who stopped semaglutide regained approximately two-thirds of lost weight within one year. A 2025 meta-analysis (Berg et al., Obesity Reviews) confirmed average weight regain of 9.69 kg across GLP agonist discontinuation studies.
The mechanistic reason: GLP-receptor agonists address chronic receptor-mediated metabolic dysregulation — appetite signaling, gastric emptying, glucose homeostasis. These are ongoing physiological conditions, not episodic injuries with repair endpoints. Discontinuation removes the pharmacological management of a chronic condition, not the conclusion of a finite treatment block.
In research models studying metabolic endpoints with GLP agonists, researchers should design protocols around continuous administration for the duration of the study period. If a washout phase is required for study design reasons, the protocol must account for the rapid reversal of metabolic effects — typically within 2–4 weeks — in outcome measurement planning.
Visual Cycle Timeline by Compound
Compound-by-Compound Cycling Reference
| Compound | Paradigm | On Phase | Off Phase | Desensitization Risk | Cycling Rationale |
|---|---|---|---|---|---|
| Sermorelin | GH Secretagogue | 8–12 weeks | 4 weeks | High | Very short t½ → pulsatile; GHS-R1a desensitization documented |
| GHRP-2 / GHRP-6 | GH Secretagogue | 8–12 weeks | 4 weeks | High | Strong GHS-R1a agonists; fastest desensitization among secretagogues |
| Ipamorelin | GH Secretagogue | 8–12 weeks | 4 weeks | Moderate | More selective than GHRP-6; lower desensitization rate; same cycling framework applies |
| Tesamorelin | GH Secretagogue | Varies by protocol | Protocol-specific | Moderate | FDA-approved continuous protocol exists; research cycling varies by endpoint |
| BPC-157 | Tissue Repair | 4–8 weeks (endpoint) | 2–4 weeks post-endpoint | Low | Angiogenic/GF signaling — no GHS-R1a; goal-oriented not calendar-driven |
| TB-500 | Tissue Repair | 4–8 weeks (endpoint) | 2–4 weeks post-endpoint | Low | Actin/cell migration pathway; endpoint-driven discontinuation |
| GHK-Cu | Tissue Repair | 4–8 weeks | 2–4 weeks | Low | Gene expression / collagen synthesis pathway; no desensitization documented |
| Selank | Neuro/Cognitive | 2–4 weeks | 1–2 weeks | Not documented | Short finite blocks standard; no formal desensitization data |
| Semax | Neuro/Cognitive | 2–4 weeks | 1–2 weeks | Not documented | ACTH analog; short use blocks standard; finite window research design |
| GLP-3 RT (Retatrutide) | Metabolic GLP | Continuous | Not cycled | Low (chronic use) | Chronic metabolic condition; discontinuation causes rapid weight regain |
| GLP-2 TRZ (Tirzepatide) | Metabolic GLP | Continuous | Not cycled | Low (chronic use) | Dual agonist; same continuous-use rationale as all GLP agonists |
| NAD+ | Coenzyme | 3 weeks | 1 week | Not applicable | Not a receptor agonist; cycling used to prevent potential enzyme suppression |
Cycling Stacked Peptide Protocols
When two peptides from different paradigms are used together, each compound follows its own cycling rules independently. They are not synchronized to a single calendar unless they share the same paradigm.
| Stack | Compound A Cycling | Compound B Cycling | Synchronization? | Notes |
|---|---|---|---|---|
| BPC-157 + TB-500 | 4–8 wks, endpoint | 4–8 wks, endpoint | Yes — same paradigm | Both tissue repair; run together, stop together at endpoint |
| BPC-157 + GH Secretagogue | 4–8 wks, endpoint | 8–12 wks on / 4 off | No — independent | Different paradigms; BPC-157 stops at tissue endpoint; GH peptide follows its own cycle |
| Selank + Semax | 2–4 wks | 2–4 wks | Yes — same paradigm | Both neuro/cognitive; finite blocks aligned; see cognitive peptides guide |
| GHK-Cu + BPC-157 | 4–8 wks | 4–8 wks, endpoint | Yes — same paradigm | Both tissue repair; aligned endpoint-driven blocks |